可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Corteva Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $8.0B | |
|---|---|---|
| Shares out | 667.2M | |
| P/E (forward) | 19.1x | |
| Dividend | $0.13 (1.16%) | |
| Volume | 14,482,667 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $15.66B | $17.46B | $17.23B | $16.91B | $17.40B | +2.7% |
| Gross profit | $6.44B | $7.02B | $17.23B | $7.38B | $8.23B | +6.3% |
| Operating income | $2.38B | $1.51B | $941.0M | $1.51B | $1.87B | -5.8% |
| Net income | $1.76B | $1.15B | $735.0M | $907.0M | $1.09B | -11.2% |
| EPS (diluted) | $2.37 | $1.58 | $1.03 | $1.30 | $1.60 | -9.4% |
| EBITDA | $3.62B | $2.73B | $941.0M | $2.74B | $3.07B | -4.0% |
| R&D | $1.19B | $1.22B | $1.34B | $1.40B | $1.47B | +5.6% |
| SG&A | $3.21B | $3.17B | $3.18B | $3.20B | $3.49B | +2.1% |
Recent company headlines from major financial publishers.
Corteva executes on its core operational strategy: Seed segment trait out-licensing continues tracking three years ahead of plan, offsetting broader crop price softening. Crop Protection new patented products touch $2.0B in FY2026, neutralizing mid-single-digit price declines in legacy chemistries. Latin American growth moderates to low-single-digit rates due to tight farmer credit. Cash generation remains robust, funding steady share repurchases and balance sheet health.
Proprietary seed trait licensing expands ahead of schedule across third-party seed networks, driving substantial margin expansion. Patented crop protection molecules and biologicals exceed commercial launch targets, capturing market share from distressed commodity competitors. Brazilian safrinha corn planted area expands briskly, lifting Latin American revenue growth above historical trend and driving diluted EPS to the high end of analyst estimates.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 5.5% | $56.4 | $58.6 | $61.2 | $64.2 | $67.7 |
| 6.0% | $52.0 | $53.6 | $55.5 | $57.6 | $60.1 |
| 6.5% | $48.4 | $49.7 | $51.7 | $52.7 | $54.6 |
| 7.0% | $45.4 | $46.5 | $47.6 | $48.9 | $50.3 |
| 7.5% | $43.0 | $43.8 | $44.7 | $45.7 | $46.8 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |